Genetic variation at a linkage disequilibrium block encompassing the cytotoxic T-lymphocyte antigen-4 (CTLA4) gene influences susceptibility to autoimmunity, but identifying the polymorphism(s) responsible for this effect has been challenging. Recently, a single-nucleotide polymorphism (SNP) located 3 0 to the known polyadenylation site of CTLA4 ( þ 6230G4A) and strongly associated with autoimmune disease was reported to regulate levels of soluble CTLA4 isoform (sCTLA4) but not the full-length isoform. The purpose of the present study is to define the mechanistic effect of the 3 0 SNP on the isoforms of CTLA4 (alternative splicing vs polyadenylation vs effects on RNA stability). However, using allele-specific single-nucleotide primer extension, we found no difference between mRNA transcripts derived from either þ 6230G4A allele in 11 heterozygous individuals, in either of the two known CTLA4 isoforms. We also found no effect of this polymorphism on ICOS (inducible costimulator), a putative downstream target. In addition, repeated attempts at 3 0 RACE (3 0 rapid amplification of cDNA ends) were unsuccessful in amplifying any contiguous sequence past the known CTLA4 polyadenylation site and no such sequence was found in the EST databases. We conclude that the mechanism of the observed association of the þ 6230 SNP with autoimmune disease remains to be determined, but does not involve modulation of steady-state mRNA of any known CTLA4 isoform.
Introduction
Genetic susceptibility to type 1 diabetes (T1D) is a complex trait. In addition to the human leukocyte antigen (HLA) and the INS-VNTR, a locus encompassing a 300 kb region on chromosome 2q23 has been consistently reported to be associated with T1D. It includes several genes encoding immunoregulatory proteins such as CD28, the cytotoxic T-lymphocyte antigen-4 (CTLA4) and the inducible costimulator (ICOS). Although any one of these genes could harbor the causative variant, most of the evidence provided by association studies in multiple ethnic groups, [1] [2] [3] and fine-mapping linkage disequilibrium (LD) studies 4, 5 strongly suggest that one or more polymorphisms within or around the CTLA4 gene region are responsible for the disease association. Associated single-nucleotide polymorphisms (SNPs) include potentially functional variants such as a À318C4T promoter SNP, a þ 49A4G base substitution resulting in a threonine ( þ 49A) to alanine ( þ 49G) amino-acid change in the signal peptide, and an (AT) n repeat in the 3 0 UTR (3 0 untranslated region), all of which are in tight LD. CTLA4 SNPs have also been associated with several autoimmune endocrinopathies, notably Graves' disease 6 (where the association is the strongest) and autoimmune thyroiditis. 6 Since all the polymorphisms listed above are in tight LD, their effects are difficult to disentangle from one another and it has been unclear as to which is the disease-predisposing polymorphism.
Recently, fine mapping in and around the CTLA4 gene region based on the testing of 108 SNPs in a Graves' disease case-control study excluded CD28 and narrowed down the association to the 3 0 region of CTLA4 and 5 0 end of ICOS (a 100 kb region of LD). 5 Within this 3 0 region, one polymorphism, þ 6230G4A (located 3 0 to the known polyadenylation site of CTLA4) conferred the highest risk to Graves' disease and autoimmune thyroiditis. 5 However, in T1D, the þ 6230G4A SNP conferred considerably lower relative risk (OR ¼ 1.15) and additional effects at the 5 0 end of CTLA4 could not be ruled out. Of potentially functional SNPs at the 5 0 end of CTLA4, regression analysis excluded the nonsynonymous þ 49A4G, but the most proximal promoter SNP, À318C4T, was not studied.
As a functional explanation for the genetic effect, Ueda et al 5 found lower CTLA4 expression levels from the chromosome carrying the G allele at þ 6230G4A. This effect was confined to an alternatively spliced form of CTLA4, lacking the transmembrane domain and encoding a secreted soluble protein (sCTLA4). The two alleles were equal in the full-length (flCTLA4) form. The mechanism remains unclear, but may involve differential splicing efficiencies and/or alternative polyadenylation. 5 In relation to the latter, Ueda et al 5 showed some evidence for the existence of transcripts containing the þ 6230 nucleotide, situated nearly 0.5 kb downstream of the known polyadenylation site. The molecular structure of those transcripts was not defined.
In a recent study of nearly 500 T1D Canadian family trios, we have confirmed the association of þ 6230A4G with T1D and also found a strong association with the most proximal promoter SNP, the À318C4T. This SNP is the only one of the CTLA4 5 0 -flanking SNPs that is located in a phylogenetically conserved region and its undertransmitted T allele (frequency ¼ 0.09) is predicted to disrupt a response element for TCF1/LEF1, a pair of transcription factors important in lymphocyte development. 7 We found that this genetic effect is independent of the þ 6230 SNP and we confirmed a previous report 8 of increased in vitro transcription of the À318T allele. 9 This transcriptional effect is relevant in vivo as we showed that, in heterozygous subjects, there was increased CTLA4 mRNA transcribed from the T allele, 9 an effect we hypothesized may be mediated by the disruption of the predicted TCF1/LEF1 site.
The purpose of this study was to (1) confirm the allelic effect in cis of the þ 6230G4A SNP on the abundance of the soluble isoform by single-nucleotide primer extension on RT-PCR products of heterozygous lymphocyte RNA samples; (2) separate this effect from that of the promoter and (3) explore possible mechanisms (effects on alternative splicing vs effects on alternative polyadenylation vs differential transcription start site for soluble vs full-length) underlying the effects (if any).
We report no observable effect of the þ 6230A4G SNP on the expression of either sCTLA4 or flCTLA4. There was also no appreciable effect on the expression of ICOS.
Results
No allelic variation attributable to þ 6230G4A in expression of either sCTLA4 or flCTLA4 We first addressed the results of a previous report showing that the level of CTLA4 mRNA transcribed from the susceptible haplotype ( þ 49G; þ 6230G) in unstimulated CD4 þ T cells from three heterozygous individuals was 2.0 to 2.5-fold lower than in those from the protective haplotype ( þ 49A; þ 6230A), but only in sCTLA4 and not in flCTLA4 transcripts. 5 To eliminate the effect of the À318C4T promoter SNP (not taken into account by Ueda et al 5 ), we selected individuals heterozygous at the marker SNP, þ 49A4G and at 6230G4A, but homozygous at À318C4T. Owing to strong LD, in the vast majority of individuals with this combination of genotypes, the A or G allele at the indicator þ 49A4G SNP marks, respectively, an A or G allele at þ 6230. We confirmed this to be the case in all the 11 samples we used, by genotyping family members. Thus, when referring to an allelic ratio of A/G, we are comparing the À318C; þ 49A; þ 6230A haplotype against the À318C; þ 49G; þ 6230G in steady-state mRNA isolated from resting PBMCs. The mean allelic ratio of A/G in flCTLA4 was 1.1470.02 (95% CI: 1.10-1.18), not statistically different from that of the sCTLA4 transcript, 1.1270.04 (95% CI: 1.05-1.19). Although a pairwise ttest between flCTLA4 and genomic DNA ratios is statistically significant (P ¼ 0.017), this difference is unlikely to be biologically significant (Table 1 and Figure 1 ). Individuals heterozygous at þ 49A4G but homozygous at þ 6230G4A (À318C; þ 49A; þ 6230G haplotype against À318C; þ 49G; þ 6230G) gave results statistically indistinguishable from the above ( 
Marker SNP is bolded. *P-value calculated for flCTLA4 vs DNA; y P-value calculated for sCTLA4 vs DNA; **P-value for flCTLA4 vs sCTLA4.
Regulatory effects of CTLA4 SNPs SM Anjos et al and Figure 1 ). Thus, our data suggest that there is no allelic variation in either sCTLA4 or flCTLA4 mRNA expression level attributable to the þ 6230G4A SNP.
Allelic variation in individuals heterozygous at the À318C4T SNP, but homozygous at the þ 6230G4A SNP To confirm our previous results, and as an additional validation of the method, we also investigated allelic variation of mRNA levels in individuals heterozygous at the promoter À318C4T SNP and at the indicator þ 49A4G, but homozygous at þ 6230G4A. We had previously reported B40% higher expression of the À318T allele vs the À318C allele in mRNA without distinguishing between full-length and soluble CTLA4 transcripts. 9 In this study, we confirm a significantly higher expression from the À318T; þ 49A; þ 6230G haplotype than À318C; þ 49G; þ 6230G in flCTLA4 transcripts, where the mean allelic ratio of A/G is 1.3670.06 (7s.e.m.) (95% CI, 1.24-1.47) vs that in genomic DNA, 1.0370.01 (7s.e.m.) (95% CI, 1.01-1.02, P ¼ 0.01) ( Table 1 and Figure 1 ) in resting T cells. Similar differences were observed in activated PBMCs (data not shown). The sCTLA4 transcript also showed statistically higher expression of the À318T; þ 49A; þ 6230G haplotype than the À318C; þ 49G; þ 6230G haplotypes in genomic DNA (P ¼ 0.02) ( Table 1 and Figure 1 ). This suggests that the À318C4T SNP, which is located in a highly conserved sequence and is predicted in silico to disrupt a transcription factor binding site, affects transcription of the flCTLA4 and sCTLA4 isoforms and is indirect evidence that the two transcripts originate from the same promoter. This effect is consistent with the independent T1D association with À318C4T but does not explain the genetic effect of þ 6230G4A. 9 Characterization of the þ 6230G4A-containing transcript In the study by Ueda et al, 5 there are two transcripts detected by Northern blot analysis in resting PBMCs: a 4.1 and 2 kb transcript. Although it is possible that the larger transcript contains the 3 0 SNP, this is not clear from this experiment. In the same study, 3 0 UTR mapping with noncontiguous RT-PCR amplicons 5 reveals that there are transcribed sequences 3 0 to the known polyadenylation site of CTLA4, one of which contains þ 6230, but not that these are part of an alternative polyadenylated CTLA4 transcript that also contains the coding sequences. We searched the EST database (http://www.ncbi.nlm.nih.-gov/BLAST) by probing the Blast algorithm with 310 bp of genomic sequence immediately 5 0 to the only known polyadenylation site (1621-1931 bp in NM_005214) and obtained 20 hits of which 12 were matches to CTLA4 sequences. All of these ESTs stopped at the known polyadenylation site and none included the þ 6230G4A SNP, nor any other downstream sequence. Thus, if a transcript exists that contains the þ 6230 SNP, its abundance must be very low, at least in the tissues and activation states covered by the EST libraries in the public databases. Our several attempts to find alternative transcripts generated by alternative polyadenylation by 3 0 Rapid Amplification of cDNA ends (3 0 RACE) were unsuccessful in obtaining sequences of alternatively polyadenylated CTLA4.
No effect of þ 6230A4G on ICOS expression Having failed to find an effect of allelic variation at þ 6230 on CTLA4, we considered the possibility that transcriptional modulation of ICOS could explain its association with Graves' disease and T1D. In an attempt to rule out allelic variation at ICOS due to remote regulatory effects from þ 6230, we examined expression of ICOS in thymus samples heterozygous for a marker SNP (rs1559931) in the 3 0 UTR. The A allele (frequency: 0.31) showed a 20-40% higher expression than the G allele (frequency: 0.69) in all samples, indicating that the polymorphism responsible for this allelic imbalance in ICOS is in perfect LD with rs1559931. Since the 3 0 UTR of Figure 1 Relative allelic abundance by CTLA4 haplotype shows significant mRNA expression differences due to the À318C4T promoter SNP and none at the þ 6230G4A SNP. Solid bar represents the mean7s.e.m. A/G allelic ratio for flCTLA4 transcripts, the dotted bar denotes the same in sCTLA4 transcripts and the grey bar represents the mean7s.e.m. A/G ratio in CTLA4 DNA. Shown are the results from three independent trials of SNuPe on n ¼ 11 individuals for CC;AG:AG haplotypes, n ¼ 3 for CC;AG;GG haplotypes and n ¼ 4 for CT;AG;GG haplotypes. The individual means7s.e.m. are summarized in Table 1 along with the statistical analysis. Regulatory effects of CTLA4 SNPs SM Anjos et al ICOS is outside the LD block containing þ 6230, this effect could not be attributed to þ 6230. This is more directly demonstrated by the presence of this effect in all þ 6230 homozygotes ( Figure 2) . Thus, the attribution of the genetic association to this SNP reported by Ueda et al, 5 cannot be explained by allelic expression effects on either ICOS or CTLA4.
Discussion
Genetic evidence supporting the association of CTLA4 with T1D is substantial. 10 Identification of the diseasecausing polymorphism or haplotype has proven to be far more challenging, due to the extent of LD in the region. To this end, detailed functional analysis is required. So far, several studies have addressed biological function of common polymorphisms of the CTLA4 gene, particularly at the signal peptide (Thr17Ala). This diseaseassociated coding polymorphism has been linked with increased proliferation of T cells 11 through a mechanism that may involve inefficient N-linked glycosylation leading to less mature CTLA-4 at the cell surface. 12 Although coding polymorphisms are likely to have functional implications, there is an obvious bias towards their identification for practical reasons, as regulatory regions are often ill-defined and can extend far beyond the open-reading frame. Their effect cannot be underestimated as cis-acting variation is thought to account for 25 to 35% of the interindividual differences, which determine susceptibility to or protection from most complex diseases and have already been identified in several diseases. 13, 14 In the case of the CTLA4 gene and autoimmune disease, compelling genetic evidence supports þ 6230G4A as the causative variant. 5 Less certain is the biological mechanism involved. Our data do not confirm the previously reported effect on sCTLA4 mRNA, a discrepancy almost certainly due to technical considerations. Ueda et al, 5 used allele-specific restriction digestion with densitometric quantification of bands, a technique less sophisticated than fluorescent primer extension, which was not validated by assaying known allele mixtures as we did in Figure 4b . It is worth noting that the results of the study given as the methodological reference for this method used by Ueda et al, evaluating a TNF-alpha promoter polymorphism for which no allelic differences were found, 15 have been contradicted in another report. 16 In addition, Ueda et al examined only three þ 6230G4A heterozygotes and their result may be a statistical artifact of small numbers. Our findings are based on a much larger number with many tightly concordant replicate determinations of each sample.
Thus, the functional basis for the CTLA4 association with autoimmunity proposed by Ueda et al, needs reevaluation. In addition to our failure to confirm the functional effect on which it was based, it lacks a clear molecular model to explain it. The SNP is not in a conserved region (more likely to harbor a functional domain 14, 17 ), and at present, it is not clear whether it is indeed part of the transcript encoding either CTLA4 splicing isoform. If, as the genetic data suggest, it is the functional variant mostly responsible for the CTLA4 association with autoimmunity, it must influence biology via an alternative mechanism not addressed in our study, such as remote effects on transcription of some gene other than CTLA4, or it may affect CTLA4 expression under a physiologic activation state of T cells not elicited in the artificial in vitro activation we employed in this study. In our search of the EST database, we did not find one single EST containing this SNP or any sequence upstream of the known polyadenylation end of CTLA4. Our data suggest that allelic variation exists at CTLA4 as a result of the À318 promoter polymorphism and we previously showed that this genetic effect was independent of the 3 0 SNP. 18 However, because of the LD structure of the region, this effect cannot explain the þ 6230 association; thus, the possibility that þ 6230 may be merely a marker for a yet unexamined variant should be reexamined. An attractive alternative explanation would be that þ 6230 modifies some enhancer element in ICOS. We did, indeed, find evidence of allele-specific differential expression of this gene in heterozygotes for a 3 0 UTR SNP. However, it was present in þ 6230G4A homozygotes and thus cannot be due to this SNP and neither can it explain its genetic effect.
Allelic-specific expression has typically been studied in relatively uncommon situations like genomic imprinting, 19, 20 but it is now accepted as a source of phenotypic variation among individuals, which cannot be accounted for by protein-altering polymorphisms. 13, 21 This phenotypic variation is at the core of complex human diseases since it is thought that subtle alterations in gene expression modulate risk to disease progression. However, if such an effect underlies the association of the þ 6230 SNP with T1D, the nature of that effect remains elusive.
Materials and methods

Sample collection
Lymphocyte samples were obtained from the peripheral blood of individuals, most of whom were nondiabetic parents of children with T1D, followed at the diabetic clinic of the Montreal Children's Hospital. Informed consent was obtained for all individuals involved in this study, approved by the Research Ethics Boards of the hospitals where recruitment took place. Thymus samples were obtained from human fetal tissue recovered from pregnancy terminations for reasons other than maternal or fetal disease. Fetal age was determined by foot length and was 10-20 weeks. Human tissue collection was approved by local ethics committees and informed consent obtained in each case. Tissues were flash frozen and stored at À701C until nucleic acid extraction. Extraction of nucleic acids has been described elsewhere. 22 Genomic DNA was extracted from whole blood by standard phenol-chloroform methods. RNA from whole blood was extracted using QIAamp RNA Blood Mini kit (Qiagen, Germany). PBMCs were obtained from whole blood by standard Ficoll gradient and 5-8 Â 10 6 cells were cultured in RPMI 1640 supplemented with 5% heatinactivated FBS, 1 mM sodium pyruvate, 2 mM b-mercaptoethanol. Total RNA was isolated from PBMCs using the Rneazy Mini Kit (Qiagen, Germany) with on column Dnase treatment or using Trizol reagent.
PCR, RT-PCR, and 3
0 RACE Reverse transcription was performed under standard conditions using random primers and 250-1000 ng of total RNA template. Primers for exon 1 of CTLA4 (includes the þ 49A4G polymorphism) in DNA were as follows: forward, 5 0 -ATGGCTTGCCTTGGATTTCA-3 0 (C1 in Figure 3 ) and reverse, 5 0 -CTTTGCAGAAGA CAGGGATG-3 0 (C-1, Figure 3 ), PCR conditions have been described elsewhere. 18 Primers used to distinguish between the soluble and full-length CTLA4 isoforms were located in, or overlapped, the alternatively spliced exon as indicated in Figure 3 . Primer sequences have been described by Ueda et al. 5 PCR conditions for amplification of soluble sCTLA4 are 941C, 5 min, followed by 30 cycles of 941C 20 s; 561C 20 s and 721C 20 s and a final extension of 6 min at 721C using Taq Polymerase (Invitrogen). The full-length CTLA4 isoform was amplified using the same conditions as described for the sCTLA4, with an annealing temperature of 601C.
Primers for amplification of ICOS 3 0 end (NCBI accession: NM_012092) are 5 0 -TCCCAGAGGCTGAAGT CACC-3 0 and 5 0 -GGGCATGCAGACAGGAAGTA-3 0 for amplification of DNA and 5 0 -AGAGCAGTGAACA CAGCCAAA-3 0 and 5 0 -GGGCATGCAGACAGGAAG TA-3 0 for cDNA amplification under standard PCR conditions. In all cases, cDNA samples did not amplify detectable products by PCR in the absence of reverse transcriptase. The RT-PCR products were used to assess allelic imbalance in samples heterozygous for the rs1559931 SNP at the 3 0 UTR of ICOS. We performed the reverse transcriptase step of 3 0 RACE using an equal mixture of the GACTCGAGTCGACATC GATTTTTTTTTTTTTTTTT(C, A and G) primers at 0.5 mg/ml and 2 mg of RNA under standard RT conditions. For the 3 0 RACE-RT-PCR, the reverse adapter primer 5 0 -GACTCGAGTCGACATCGA-3 0 (3 0 RACE-AP in Figure 3 ) was used in conjunction with a sense primer straddling part of the 5 0 UTR and exon 1 of CTLA4, 5 0 -ATGGCTTGCCTTGGATTTCA-3 0 (3 0 RACE-1, Figure 3 ) for the first round of nested PCR. A measure of 2 ml of cDNA was added to a reaction containing 200 ng each of primers, 25 mmol dNTPs in a final volume of 50 ml. Taq polymerase (0.5 U) were added following a hot start at 941C 3 min; 721C 3 min. The cycling conditions were: 941C 30 s; 601C 30 s; 721C 2 min 30 s; 30 cycles, with a final extension at 721C for 10 min. In the second round of nested PCR, a forward primer in the known 3 0 UTR of CTLA4 (NCBI accession NM_005214), 5
0 -GTATGACC TTCTAGGAAGCTCCAGTTC-3 0 (3 0 RACE-2, Figure 3 ) was used along with the same reverse primer used in the first round of PCR. PCR (1 ml) from the first round was used as template for the second round of the nested PCR under the following conditions: 951C 3 min after which 0.5 U Taq Reactions were performed in a total volume of 10 ml, containing 2 ml of treated PCR product, 4.5 ml of SnaPshot kit, 2.5 ml of water and 2.5 mM extension primer. Primer extension thermocycling conditions consisted of an initial step of 951C 2 min, followed by 25 cycles of 951C for 5 s, 431C for 5 s, and 601C for 5 s. Following primer extension, reaction products were treated with 1.0 U SAP for 1 h at 371C and then for 15 min at 751C. Aliquots of 1 ml SnaPshot reaction product were combined with 9 ml of Hi-Di Formamide and loaded onto a 3100 DNA sequencer (Applied Biosystems, CA, USA). We electrophoresed products on a 36-cm capillary array at 601C and processed the data by using Genescan Analysis version 3.7 software (Applied Biosystems, CA, USA). Peak heights representing allele-specific extended primers were determined using Genescan (Applied Biosystems, CA, USA) and were used to give a ratio of allelic representation.
Allele expression assay All individuals were initially genotyped in order to identify heterozygotes for the marker polymorphisms. 18 The transcribed signal peptide polymorphism, 49A4G, was used to distinguish RNA alleles. We confirmed phase with the À318C4T (rs# 5742909) and þ 6230A4G loci by genotyping family members. We compared expression of alleles in three genotypes, all heterozygous at þ 49A4G: the common À318C;49G; þ 6230G vs À318C;49A; þ 6230A, the less common À318T;49A; þ 6230G vs À318C;49G; þ 6230G, and the rare À318C; þ 49A; þ 6230G vs À318C; þ 49G; þ 6230G. In order to achieve isoform-specific amplification, we used different primers for DNA and RNA, which may introduce artifacts related to secondary structure during the SNuPe reaction. 23 We corrected this by digesting our PCR and RT-PCR products with a restriction enzyme (HaeIII, Invitrogen) in order to generate fragments of identical size prior to SNuPe. Results were identical whether this digestion step was included or omitted. Each cDNA sample was assayed alongside its corresponding heterozygote genomic DNA to ensure uniformity in reaction and assay conditions and samples were tested four times in this manner by using two separate RT reactions. The ratio of one allele over the other (A/G for CTLA4 and T/C for ICOS) was the readout for the allelic imbalance assay. The ratios observed in genomic DNA represent 1 : 1 stoichiometry of the two alleles, but where cis-acting variation exists, mRNA originating from one chromosome will be expressed at a higher level than that of its sister chromosome and this will be detected by changes in the ratio of abundance of each allele. To account for differences in probe and fluorochrome efficiencies, the cDNA sample ratio was divided by the average genomic ratio for that assay batch. 23 We validated the assay by mixing, in predetermined proportions, PCR products derived from DNA homozygous for each allele and performing primer extension analysis on 17.5 ng/ml of mixed DNA. In doing so, we show that there is excellent correlation between observed and expected allelic ratios (Figures 4a and b) .
Statistical analysis DNA measurements in a given assay were used to estimate the technical variance of the assay and the lower limit of detectable allelic imbalance for that assay. Mean72 s.d. for the DNA ratios ranged from 0.97 to 1.09 for the CTLA4 allelic imbalance SNP and from 1.04 to 1.16 for ICOS. Therefore, RNA results outside these ranges were considered statistically significant. Differences in RNA ratios between different genotypes were evaluated pairwise by individual t-test, given the small number of comparisons made. , the x-axis denotes the known mixed proportions of each allele plotted against the observed on the y-axis upon subjecting the mix to SNuPe, plotted for each allele.
